Introduction
============

Nasopharyngeal carcinoma (NPC) is a cancer of the head and neck region arising from the nasopharynx epithelium.[@b1-ott-11-3205],[@b2-ott-11-3205] It has an extremely unique pattern of geographical distribution, and most new cases are in Eastern and Southeastern Asia.[@b1-ott-11-3205]--[@b3-ott-11-3205] Current therapeutic decisions are based mainly on disease stage.[@b1-ott-11-3205],[@b4-ott-11-3205],[@b5-ott-11-3205] The contemporary consensus is to treat early-stage disease with radiotherapy alone, and advanced stage disease with radiotherapy and concurrent chemotherapy.[@b1-ott-11-3205],[@b4-ott-11-3205],[@b5-ott-11-3205]

Although localized disease can be effectively controlled with radiotherapy alone, distant metastasis is a critical challenge, and the treatment outcome of metastatic NPC remains disappointing.[@b1-ott-11-3205],[@b4-ott-11-3205],[@b5-ott-11-3205] Many clinicopathologic variables have been reported to predict treatment outcome. Among these, TNM staging is still the most important prognostic factors in NPC.[@b1-ott-11-3205],[@b4-ott-11-3205],[@b5-ott-11-3205] However, patients with the same clinical stage often undergo substantially different clinical courses and outcomes. Thus, new biomarkers for more precise prognostic prediction in NPC should be explored.

During disease progression or metastasis, cancer cells migrate through the extracellular matrix (ECM) for intravasation into the blood and lymphatic vessels.[@b6-ott-11-3205] Many cell adhesion molecules participate in this process.[@b6-ott-11-3205] Through data mining on a published transcriptome of NPC in the Gene Expression Omnibus dataset (GEO, NCBI, Bethesda, MD, USA) with a focus on cell adhesion (GO:0007155), we identified *FN1* (encoding fibronectin 1) and *POSTN* (encoding periostin) as the two most significantly upregulated genes in NPC tumorigenesis. We found that *FN1* was the most significantly upregulated gene involving cell migration in NPCs.[@b7-ott-11-3205] High FN1 expression was significantly associated with worse clinical outcomes.[@b7-ott-11-3205] POSTN, also known as osteoblast-specific factor 2, is a component of the ECM involved in regulating intercellular adhesion.[@b8-ott-11-3205] Recent studies have shown that POSTN is involved in tumorigenesis and tumor progression of various tumors, such as breast, lung, prostate and ovarian cancer.[@b8-ott-11-3205]--[@b11-ott-11-3205] In prostate cancer, POSTN overexpression was associated with poorly differentiated tumors and advanced cancer stage and was correlated with clinical outcome, including PSA recurrence-free survival and overall survival.[@b8-ott-11-3205] Therefore, we further investigated the association between POSTN expression and prognosis in NPC ([Figure 1](#f1-ott-11-3205){ref-type="fig"}).

Materials and methods
=====================

Analysis of expression profile
------------------------------

Through data mining of the Gene Expression Omnibus database (National Center for Biotechnology Information, Bethesda, MD, USA), we identified one dataset, GSE12452, obtained using the Affymetrix Human Genome U133 Plus 2.0 Array platform by analysis of 31 NPC tissues, and 10 normal nasopharyngeal tissues. We imported the raw files and computed the gene expression levels identified by probe sets, without preselection or filtering, using Nexus Expression 3 software (BioDiscovery, EI Segundo, CA, USA). Supervised comparative analysis and functional profiling were performed to identify statistically significant differentially expressed genes, with special attention to genes with molecular function involving cell adhesion (GO:0007155). Only genes showing significantly different expression (log2 ratio \>3, *p*\<0.01) were selected.

Patients and tumor samples
--------------------------

On the basis of the Declaration of Helsinki and local ethic regulations, the institutional review board (IRB) of Chi Mei Medical Center approved this study (IRB10302013). In this study, the IRB of Chi Mei Medical Center granted the research use of formalin-fixed materials from BioBank of Chi Mei Medical Center and waived the need of informed consents from participants due to anonymous processing for research purpose that excluded the identification of personal information of participants. Available paraffin-embedded tissue blocks were retrieved from 124 patients with NPC diagnosed between January 1993 and December 2002. These patients showed no signs of distant metastasis at first presentation and underwent biopsy at initial diagnosis. Two pathologists reappraised the histological subtypes according to the current World Health Organization (WHO) classification. The tumor staging was reevaluated using the 7th American Joint Committee on Cancer (AJCC) system.[@b12-ott-11-3205]

Immunohistochemistry
--------------------

Tissue sections were cut from paraffin-embedded blocks at 3 μm thickness as described previously.[@b13-ott-11-3205],[@b14-ott-11-3205] Slides were processed followed by deparaffinization, rehydration, antigen retrieval, and blockage of endogenous peroxidase. Subsequently, the sections were incubated with the primary antibody against POSTN (1:100; Lifespan BioScience, Seattle, WA, USA, Cat No LS-B3986) for 1 hour. We detected the primary antibody based on the ChemMate DAKO EnVision Detection Kit (K5001, Carpinteria, CA, USA). To ensure the quality of immunostaining, tissues sections incubated without the primary antibody were used as negative controls.

Two pathologists who were blinded to the study scored the intensity and distribution of positive immunostaining tumor cells using a multiheaded microscope to reach a consensus on the H-score, using the following equation: ΣPi(*i*+1), where *i* is the intensity of stained tumor cells (0 to 3+), and Pi is the percentage of stained tumor cells, varying from 0% to 100%.[@b15-ott-11-3205] The immunoreactivity of POSTN was dichotomized into high and low expression according to the median H-score of 205.

Treatment and follow-up
-----------------------

All patients received a complete course of radiotherapy with the daily fractioned dose of 180--200 cGy at five fractions weekly, to achieve a total dose of ≧7,000 cGy. Those with stage II--IV disease also received cisplatin-based chemotherapy following published protocols.[@b16-ott-11-3205] Patient response was classified according to the previously reported WHO criteria.[@b17-ott-11-3205] In total, this study included 110 complete and 7 partial responders.

### Cell culture

Dysplastic keratinocyte (DOK), NPC-derived HONE1 and TW01 cell lines were obtained from European Collection of Animal Cell Cultures (ECACC), American Type Culture Collection (ATCC), and Food Industry Research and Development Institute, Taiwan, respectively. The culture conditions of DOK, HONE1, and TW01 cell lines were previously described.[@b18-ott-11-3205] Briefly, all cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM), supplemented with 10% fetal bovine serum, 100 μg/mL streptomycin, and 100 units/mL penicillin at a 37°C, 5% CO~2~ humidified incubator.

### Western blot analysis

Equal amounts of total protein (25 μg) extracted from the cell lines were separated on 10% sodium dodecylsulfate polyacrylamide gel electrophoresis gel NuPAGE (Invitrogen), and transferred to polyvinylidene difluoride membranes (Amersham Biosciences, Bucks, UK). After blocking, the membranes were probed with the primary antibodies against POSTN (1:50; Lifespan BioScience, Cat No LS-B3986). Glyceraldehyde 3-phosphate dehydrogenase was used as the loading control (Clone 6C5, 1:10,000; Millipore, Beverly, MA, USA). After incubation with the secondary antibody, the protein expression was visualized using the enhanced chemiluminescence system (Amersham Biosciences).

Statistical analyses
--------------------

All statistical analyses were performed using SPSS^®^ V.17.0. The associations of POSTN expression with various clinicopathologic features were evaluated by Pearson's chi-square test. We analyzed three end points, including disease-specific survival (DSS), distant metastasis-free survival (DMFS), and local recurrence-free survival (LRFS). DSS, DMFS, and LRFS were calculated from the starting date of radiotherapy to the date of development of an event. Univariate survival analyses were performed using Kaplan--Meier plots, and survival was evaluated by the log-rank test. In the multivariate Cox proportional hazards regression model, all significant parameters at the univariate level were entered to compare their independent prognostic effects. For all analyses, we used two-sided tests of significance with *p*\<0.05 being considered significant.

Results
=======

POSTN transcript is significantly upregulated in NPC
----------------------------------------------------

From the public transcriptomic dataset of 31 NPC cases, we focused on the genes involved in the regulation of cell adhesion. We found that only six probes covering three genes showed significant overexpression during NPC development. *FN1* and *POSTN* were the most significantly upregulated genes in NPC. Our previous study has shown that *FN1* was the most significantly upregulated gene involved in cell migration in NPC.[@b7-ott-11-3205] We selected *POSTN* for further validation due to the significant statistical power (*p*\<0.0001) and the prominent log2-transformed expression level (log2 ratio: 3.38; [Figure 2](#f2-ott-11-3205){ref-type="fig"} and [Table 1](#t1-ott-11-3205){ref-type="table"}).

Association between POSTN expression and clinicopathologic features of NPC
--------------------------------------------------------------------------

Of 124 patients with NPC, 95 (76.6%) were men and 29 (23.4%) were women, and their mean age was 48.6 years (range, 20--83). A total of 114 patients were monitored regularly after radiotherapy, with 3--141 months of follow-up (mean, 67.0 months). According to the AJCC stage, 7 (5.6%), 31 (25.0%), 46 (37.1%), and 40 (32.3%) cases were classified as stage I, II, III, and IV, respectively. With regard to histological subtypes, 5 (4.0%) patients had keratinizing squamous cell carcinomas, 54 (43.5%) had non-keratinizing differentiated carcinomas, and 65 (52.4%) patients had non-keratinizing, undifferentiated carcinomas.

During follow-up, 59 (47.6%) patients died of the disease, 49 (39.5%) developed distant tumor metastasis, and 37 (29.8%) patients had local tumor recurrence. Whether with squamous metaplasia or not, POSTN immunoexpression was rarely found in cases of non-neoplastic nasopharyngeal mucosal epithelia ([Figure 3A and B](#f3-ott-11-3205){ref-type="fig"}). However, positive staining was identified in some tumor tissues ([Figure 3C and D](#f3-ott-11-3205){ref-type="fig"}). High POSTN expression was significantly associated with lymph node metastasis (*p*=0.004) and advanced AJCC stage (*p*=0.006; [Table 2](#t2-ott-11-3205){ref-type="table"}).

Prognostic significance of POSTN expression
-------------------------------------------

Univariate and multivariate analyses were performed to evaluate the prognostic significances of POSTN expression. Univariate analysis revealed that primary tumor stage, lymph node status, AJCC stage, and POSTN expression were significantly associated with DSS, DMFS, and LRFS ([Table 3](#t3-ott-11-3205){ref-type="table"}). In multivariate Cox regression analysis, POSTN expression and AJCC stage remained independently associated with DSS (HR: 2.311; 95% CI: 1.327--4.027; *p*=0.003) and LRFS (HR: 3.187; 95% CI: 1.108--4.408; *p*=0.024) together with AJCC stage ([Table 4](#t4-ott-11-3205){ref-type="table"}). Kaplan--Meier analysis also showed that high POSTN expression also predicted significantly worse DSS (*p*=0.0002, [Figure 4A](#f4-ott-11-3205){ref-type="fig"}), DMFS (*p*=0.0138, [Figure 4B](#f4-ott-11-3205){ref-type="fig"}), and LRFS (*p*=0.0028, [Figure 4C](#f4-ott-11-3205){ref-type="fig"}).

We also evaluated POSTN endogenous protein expression in a non-tumor, premalignant keratinocyte (DOK) and two NPC cells. Of note, POSTN was significant higher expression in both HONE1 and TW01 cells than in DOK ([Figure 5](#f5-ott-11-3205){ref-type="fig"}), implicating its potential tumorigenic role in NPC.

Discussion
==========

NPC is characterized as a clinically heterogeneous malignancy. Patients with the same cancer staging present different risks of local tumor recurrence, distant metastasis, and cancer mortality.[@b1-ott-11-3205]--[@b5-ott-11-3205] In Taiwan, NPC is the second most common cancer in incidence and mortality among head and neck cancers. Therefore, identifying molecular markers for early prediction of cancer progression may help physicians stratify patients according to varying risks and to decide the treatment program. In this study, high POSTN expression was significantly associated with tumor aggressiveness. Furthermore, we demonstrated the association of POSTN expression with LRFS and DSS after adjusting AJCC stage in patients with NPC. The risk of cancer-related death and distant metastasis was increased two fold and that of local tumor recurrence increased by three fold in patients with NPC with high POSTN expression. These findings indicate that POSTN status can also be a clinicopathologic predictor to improve risk stratification for NPC patients.

Human POSTN is encoded by a gene located on chromosome 13 (13q13.3).[@b19-ott-11-3205] POSTN has been found in various normal tissues and organs, including the lungs, testis, thyroid, stomach, vagina, ovary, colon, prostate, and breast.[@b20-ott-11-3205],[@b21-ott-11-3205] The encoded glycoprotein plays important roles in the physiological process of epithelial--mesenchymal transition (EMT), which is necessary for proper embryogenesis.[@b20-ott-11-3205],[@b21-ott-11-3205] POSTN is also an ECM protein involved in regulating intercellular adhesion through interactions with other ECM proteins, such as fibronectin, tenascin-C, and collagen V.[@b8-ott-11-3205],[@b22-ott-11-3205],[@b23-ott-11-3205] The ECM protein POSTN was found to be a marker and an inducer of EMT, a process that is characterized by the dissemination of primary tumor epithelial cells to the sites of metastasis and the dedifferentiation program that leads to cancer progression.[@b24-ott-11-3205],[@b25-ott-11-3205]

Increased POSTN expression has been found in many malignancies, including breast, lung, colorectal, stomach, pancreatic, prostate, and ovarian cancer.[@b8-ott-11-3205]--[@b11-ott-11-3205] POSTN mRNA and protein expression are higher in breast cancer tissue than in normal breast tissue. POSTN expression was significantly associated with tumor size, and expression of progesterone and estrogen receptor, vascular endothelial growth factor R1, R2, and A.[@b26-ott-11-3205] Moreover, POSTN has been shown to promote cell survival and induce tumor angiogenesis in breast cancer.[@b24-ott-11-3205],[@b27-ott-11-3205] In lung cancer, some researchers demonstrated significant association between POSTN expression and tumor size, disease stage, lymph node metastasis, and lymphatic invasion.[@b28-ott-11-3205] High POSTN expression is also significantly related to cancer progression and worse patients' outcomes.[@b28-ott-11-3205] In head and neck squamous cell carcinoma, Kudo et al demonstrated that POSTN overexpression promoted tumor invasion, anchorage-independent growth, metastasis, and lymph angiogenesis.[@b29-ott-11-3205],[@b30-ott-11-3205]

Although the exact roles and signaling pathways involving POSTN in NPC tumorigenesis and cancer metastasis are still unclear, POSTN expression may be an indicator of a special subtype of NPC with aggressive pathologic features and worse prognosis. In breast and lung cancers, POSTN binds to integrins and activates Akt/PKB- and FAK-mediated signaling pathways, enhancing tumor invasion, metastasis, and angiogenesis.[@b31-ott-11-3205] Interestingly, a POSTN-targeting positron emission tomography probe has been developed and applied in the preclinical setting for noninvasive assessment of the tumor microenvironment in esophageal cancer.[@b32-ott-11-3205] However, further studies are needed to elucidate the significant molecular pathways involving POSTN in NPC.

There are several limitations to this study. First, this is a retrospective single-center study. Second, we could not elucidate the exact molecular mechanism causing adverse outcome in POSTN-overexpressing NPC. Third, variations exist in immunohistochemistry by using different scoring system. In this study, we evaluated both the percentage and intensity of positively stained tumor cells to generate an H-score because of its excellent correlation to Western blot assay.[@b33-ott-11-3205] Besides, all slides were scored by two independent pathologists to minimize divergence and to reach a consensus for each case. Finally, prospective multi-institutional studies with a larger cohort are warranted to certify our observations.

Conclusion
==========

We performed data mining and evaluated the prognostic significance of POSTN immunoexpression in a well-characterized series of patients with NPC. We found that POSTN expression is independently associated with cancer-specific mortality and tumor recurrence in patients with NPC. Our findings reinforce the potential role of POSTN in contributing to the aggressive behavior of NPC and may help risk-stratify patients. Moreover, our results justify the potential of anti-POSTN targeted therapy for NPC patients in the future.
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![Flow chart of research.\
**Abbreviations:** NPC, nasopharyngeal carcinoma; *POSTN*, periostin.](ott-11-3205Fig1){#f1-ott-11-3205}

![By reappraising the published transcriptomic datasets of NPC vs non-neoplastic nasopharyngeal tissues samples (GSE12452), with special attention to those associated with cell adhesion (GO:0007155),\
**Notes:** *POSTN* was found to be one of the most significantly upregulated genes.\
**Abbreviations:** NPC, nasopharyngeal carcinoma; *POSTN*, periostin.](ott-11-3205Fig2){#f2-ott-11-3205}

![Periostin immunoexpression.\
**Notes:** In normal nasopharyngeal mucosa (**A**) and that with (**B**) squamous metaplasia, periostin staining is barely detected. Representative low-stage NPC (**C**) shows weak periostin staining; whereas the high-stage lesion (**D**) exhibits diffuse and strong staining. Scale bar=100 μm; magnification ×400.\
**Abbreviation:** NPC, nasopharyngeal carcinoma.](ott-11-3205Fig3){#f3-ott-11-3205}

![Kaplan--Meier survival curves in the NPC patients according to POSTN immunoexpression.\
**Note:** POSTN immunohistochemical overexpression is a strong prognosticator of worse disease-specific survival (**A**), distant metastasis-free survival (**B**), and local recurrence-free survival (**C**).\
**Abbreviations:** NPC, nasopharyngeal carcinoma; POSTN, periostin.](ott-11-3205Fig4){#f4-ott-11-3205}

![Western blot of endogenous POSTN expression in NPC cells.\
**Notes:** POSTN was significantly higher expressed in both HONE1 and TW01 NPC cells than in non-tumor DOK cell.\
**Abbreviations:** DOK, dysplastic keratinocyte; NPC, nasopharyngeal carcinoma; POSTN, periostin.](ott-11-3205Fig5){#f5-ott-11-3205}

###### 

Summary of differentially expressed genes associated with cell adhesion identified in the transcriptome of nasopharyngeal carcinoma

  Probe          Comparison log ratio   Comparison *p*-value   Gene symbol   Gene name                                                             Biological process                                                                                                                                                                           Molecular function
  -------------- ---------------------- ---------------------- ------------- --------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------
  217109_at      −5.9951                \<0.00001              *MUC4*        Mucin 4; cell surface associated                                      Cell adhesion, cell-matrix adhesion                                                                                                                                                          ErbB-2 class receptor binding, extracellular matrix structural constituent, protein binding
  217110_s\_at   −5.4909                \<0.00001              *MUC4*        Mucin 4; cell surface associated                                      Cell adhesion, cell-matrix adhesion, transport                                                                                                                                               ErbB-2 class receptor binding, extracellular matrix structural constituent, protein binding, transporter activity
  238720_at      −5.1279                \<0.00001              *OMG*         Oligodendrocyte myelin glycoprotein                                   Cell adhesion                                                                                                                                                                                GPI anchor binding, protein binding
  209114_at      −4.9189                \<0.00001              *TSPAN1*      Tetraspanin 1                                                         Cell adhesion, cell motility, cell proliferation                                                                                                                                             Protein binding, thiamine uptake transmembrane transporter activity
  211719_x\_at   4.3873                 \<0.00001              *FN1*         Fibronectin 1                                                         Acute-phase response, cell adhesion, cell migration, response to wounding, transmembrane receptor protein tyrosine kinase signaling pathway                                                  Collagen binding, extracellular matrix structural constituent, heparin binding, protein binding
  204895_x\_at   −4.2689                \<0.00001              *MUC4*        Mucin 4; cell surface associated                                      Cell adhesion, cell-matrix adhesion, transport                                                                                                                                               ErbB-2 class receptor binding, extracellular matrix structural constituent, protein binding, transporter activity
  220196_at      −4.0657                \<0.00001              *MUC16*       Mucin 16; cell surface associated                                     Cell adhesion                                                                                                                                                                                Protein binding
  212464_s\_at   4.0197                 \<0.00001              *FN1*         Fibronectin 1                                                         Acute-phase response, cell adhesion, cell migration, response to wounding, transmembrane receptor protein tyrosine kinase signaling pathway                                                  Collagen binding, extracellular matrix structural constituent, heparin binding, protein binding
  210495_x\_at   3.6034                 \<0.00001              *FN1*         Fibronectin 1                                                         Acute-phase response, cell adhesion, cell migration, response to wounding, transmembrane receptor protein tyrosine kinase signaling pathway                                                  Collagen binding, extracellular matrix structural constituent, heparin binding, protein binding
  216442_x\_at   3.5853                 \<0.00001              *FN1*         Fibronectin 1                                                         Acute-phase response, cell adhesion, cell migration, response to wounding, transmembrane receptor protein tyrosine kinase signaling pathway                                                  Collagen binding, extracellular matrix structural constituent, heparin binding, protein binding
  205328_at      −3.5736                \<0.00001              *CLDN10*      Claudin 10                                                            Calcium-independent cell-cell adhesion, cell adhesion                                                                                                                                        Identical protein binding, protein binding, structural molecule activity
  214385_s\_at   −3.5388                \<0.00001              *MUC5AC*      Mucin 5AC; oligomeric mucus/gel-forming                               Cell adhesion, digestion, fibril organization and biogenesis                                                                                                                                 Extracellular matrix constituent; lubricant activity, extracellular matrix structural constituent, protein binding
  232306_at      −3.4379                \<0.00001              *CDH26*       Cadherin-like 26                                                      Cell adhesion, homophilic cell adhesion                                                                                                                                                      Calcium ion binding, protein binding
  210809_s\_at   3.3769                 \<0.00001              *POSTN*       Periostin; osteoblast specific factor                                 Cell adhesion, skeletal development                                                                                                                                                          Heparin binding, protein binding
  201505_at      3.0358                 \<0.00001              *LAMB1*       Laminin; beta 1                                                       Cell adhesion, neurite development, odontogenesis, positive regulation of cell migration, positive regulation of epithelial cell proliferation                                               Extracellular matrix structural constituent, protein binding, structural molecule activity
  204591_at      −3.0226                \<0.00001              *CHL1*        Cell adhesion molecule with homology to L1CAM (close homolog of L1)   Axon guidance, behavior, cell adhesion, cell differentiation, multicellular organismal development, nervous system development, neurite development, neuron migration, signal transduction   Protein binding

**Abbreviation:** *POSTN*, periostin.

###### 

Associations of periostin expression with other important clinicopathologic variables

  Parameters           Category      Periostin expression, n   *p*-value   
  -------------------- ------------- ------------------------- ----------- ---------------------------------------------------
  Gender               Male          43                        52          0.056
  Female               19            10                                    
  Age (years)          \<60          51                        47          0.378
  ≥60                  11            15                                    
  Primary tumor (T)    T1--T2        42                        38          0.453
  T3--T4               20            24                                    
  Nodal status (N)     N0--N1        36                        20          0.004[\*](#tfn2-ott-11-3205){ref-type="table-fn"}
  N2--N3               26            42                                    
  Stage                I--II         26                        12          0.006[\*](#tfn2-ott-11-3205){ref-type="table-fn"}
  III--IV              36            50                                    
  Histological grade   Keratinized   3                         2           0.814
  Non-keratinized      28            26                                    
  Undifferentiated     31            34                                    

**Note:**

Statistically significant.

###### 

Univariate log-rank analyses

  Parameters                        Category                           No of cases   DSS   DMFS                                                 LRFS                                                             
  --------------------------------- ---------------------------------- ------------- ----- ---------------------------------------------------- ------ ---------------------------------------------------- ---- ----------------------------------------------------
  Gender                            Male                               95            45    0.7870                                               38     0.6128                                               30   0.3240
  Female                            29                                 14                  11                                                          7                                                         
  Age (years)                       \<60                               98            48    0.8600                                               42     0.3091                                               29   0.8206
  ≥60                               26                                 11                  7                                                           8                                                         
  Primary tumor (T)                 T1--T2                             80            32    0.0289[\*](#tfn3-ott-11-3205){ref-type="table-fn"}   25     0.0085[\*](#tfn3-ott-11-3205){ref-type="table-fn"}   19   0.0180[\*](#tfn3-ott-11-3205){ref-type="table-fn"}
  T3--T4                            44                                 27                  24                                                          18                                                        
  Nodal status (N)                  N0--N1                             56            18    0.0008[\*](#tfn3-ott-11-3205){ref-type="table-fn"}   17     0.0132[\*](#tfn3-ott-11-3205){ref-type="table-fn"}   12   0.0160[\*](#tfn3-ott-11-3205){ref-type="table-fn"}
  N2--N3                            68                                 41                  32                                                          25                                                        
  Stage                             I--II                              38            10    0.0020[\*](#tfn3-ott-11-3205){ref-type="table-fn"}   9      0.0072[\*](#tfn3-ott-11-3205){ref-type="table-fn"}   5    0.0026[\*](#tfn3-ott-11-3205){ref-type="table-fn"}
  III--IV                           86                                 49                  40                                                          32                                                        
  Histological grade                Keratinized/non-keratinized        47            20    0.1980                                               17     0.2753                                               15   0.9521
  Undifferentiated                  77                                 39                  32                                                          22                                                        
  Periostin                         Low expression (H-score\<median)   62            20    0.0002[\*](#tfn3-ott-11-3205){ref-type="table-fn"}   20     0.0138[\*](#tfn3-ott-11-3205){ref-type="table-fn"}   13   0.0028[\*](#tfn3-ott-11-3205){ref-type="table-fn"}
  High expression (H-scor≥median)   62                                 39                  29                                                          24                                                        

**Note:**

Statistically significant.

**Abbreviations:** DMFS, distal metastasis-free survival; DSS, disease-specific survival; LRFS, local recurrence-free survival.

###### 

Multivariate survival analyses

  Parameter        Category   DSS            DMFS                                                LRFS                                                                                                                                                  
  ---------------- ---------- -------------- --------------------------------------------------- ------- -------------- --------------------------------------------------- ------- -------------- --------------------------------------------------- --
  Stage            I--II      1                                                                          1                                                                          1                                                                  
  III--IV          2.235      1.113--4.488   0.024[\*](#tfn5-ott-11-3205){ref-type="table-fn"}   2.275   1.086--4.767   0.029[\*](#tfn5-ott-11-3205){ref-type="table-fn"}   2.210   1.222--8.316   0.018[\*](#tfn5-ott-11-3205){ref-type="table-fn"}   
  Periostin exp.   Low exp.   1                                                                          1                                                                          1                                                                  
  High exp.        2.311      1.327--4.027   0.003[\*](#tfn5-ott-11-3205){ref-type="table-fn"}   1.727   0.962--3.100   0.067                                               3.187   1.108--4.408   0.024[\*](#tfn5-ott-11-3205){ref-type="table-fn"}   

**Note:**

Statistically significant.

**Abbreviations:** DSS, disease-specific survival; DMFS, distal metastasis-free Survival.
